Tag: Loss of Proteostasis

Scientists have found a pathway that regulates protein aggregation, a cause of several age-related neurodegenerative diseases. United by abnormal protein aggregation Most neurodegenerative diseases are age-related, and many of them are similar in other ways. For instance, amyotrophic lateral sclerosis (ALS), Huntington’s disease, and Alzheimer’s disease have all been linked to abnormal protein aggregation [1],...

Researchers publishing in Nature Aging have discovered how Alzheimer's-related protein aggregates are also related to senescent cells and osteoporosis. Beyond the brain Why We Age: Loss of ProteostasisThe loss of proteostasis is the failure of the protein-building machinery of the cell and the accumulation of misfolded proteins, which is one of the root causes of...

In Aging Cell, researchers have explored how transcription factor EB (TFEB) promotes proteostasis in a common aging model. Maintaining protein function Why We Age: Loss of ProteostasisThe loss of proteostasis is the failure of the protein-building machinery of the cell and the accumulation of misfolded proteins, which is one of the root causes of age-related...

Research published in Aging Cell has revealed that a nematode species commonly used for aging research lives much longer on an alternate-day fasting regimen, but only when it is administered in middle age and only when the worms are consuming an animal-based protein source. Deciding what to restrict and when Dietary restriction practices have been...

With an in-depth examination tool in hand, researchers publishing in Aging have done a preliminary examination of the muscle protein differences between younger and older people and how older people's proteins change with exercise. The power to take a close look This paper begins with a discussion of proteomics, the science of analyzing what proteins...

A pair of neurologists have published a review in Cell discussing the current state of Alzheimer's therapies, including drugs in early development, treatments in clinical trials, and therapies that are prescribed today. The -mab drugs Monoclonal antibodies, drugs whose names end in -mab, have become the go-to approach for pharma companies seeking to develop anti-Alzheimer's...